Odronextamab
Based on 1 Customer Validation
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research.
For research use only. We do not sell to patients.
- Purity : 99.50%
- CAS No.: 1801338-64-6
- Molecular Weight:144 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD3E & MS4A1
In Vitro
Odronextamab (1-10 nM, 48-96 h) at a low picomolar concentration, mediates cytotoxicity of all tested CD20-expressing lymphoma cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human peripheral blood mononuclear cells, CD20-expressing Nalm6 tumor cells
-
Concentration:1-10 nM
-
Incubation Time:48-96 h
-
Result:At a low picomolar concentration of was capable of mediating cytotoxicity of all CD20-expressing lymphoma cells tested; EC50 values for cytotoxicity were in a range of 3-25 pM.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Raji cell xenograft tumor mice model[2]
-
Dosage:0.04, 0.1, 0.4, 1.0 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Treatment at doses of 0.4 or 1 mg/kg in mice resulted in complete tumor suppression. In mice receiving 0.04-0.1 mg/kg concentrations of odronextamab, tumor growth was slowed.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 Raji cells with Odronextamab (HY-P99038, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Flow cytometric analysis of 1X106 Jurkat cells with Odronextamab (HY-P99038, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1801338-64-6
-
Appearance Liquid
-
Molecular Weight 144 kDa
-
Color Colorless to light yellow
-
SMILES
[Odronextamab]
-
Synonyms
REGN1979
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Rajat Bannerji, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet H [Content Brief]
[2]. Zhu M, et al. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. Clin Transl Sci. 2022 Apr;15(4):954-966. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)